Welcome to BioLegend’s one-of-a-kind advanced search. Search by any one of the single fields below or narrow down your searches by using multiple parameters. Looking for an anti-mouse NK cell antibody for IHC? Or looking for a FITC-conjugated antibody against a human marker for dendritic cells to use for flow cytometry? Only BioLegend’s advanced search can provide you with the best answers. If you have further questions, please contact our technical service team at 858-768-5801.
Catalog Number
Specificity
GeneID
Clone
Format
Species Reactivity
Applications
Cell Type
Keywords
*To perform a multi-parameter search, be sure to click on "Match all fields" below:
Match all fields
Match any field
Exact match
Partial match
Use this document lookup tool to find Current Product Datasheets, Certificates of Analysis, or MSDS for any antibody products you have purchased from BioLegend.
Use the search box below to perform a site search of BioLegend.com powered by Google™.
Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is ≤ 1.0 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
COA:
Enter Lot#:
Application Notes:
Additional reported applications (for the relevant formats) include: Western blotting1, immunoprecipitation2, immunohistochemistry2, and ELISA detection2. The biotinylated B08-35 antibody is useful as a detection antibody for a sandwich ELISA assay, when used in conjunction with the purified B08-9103 antibody (Cat. No. 333301/333302) as capture antibody.
Application References:
1. Hsu TL, et al. 2005. J. Immunol. 175:5135. (WB) 2. Personal communication (IP IHC ELISA Detection) 3. Tai SK, et al. 2012. J. Immunol. 188:2464. PubMed.
Formalin-fixed, paraffin-embedded human tissues were stained with 5 µg/ml B08-35, followed by incubation with biotinylated goat anti-mouse secondary antibody, followed by HRP-streptavidin. Staining was visualized with DAB peroxidase substrate and counterstained with hematoxylin. Immunohistochemical staining of DcR3 expression is shown for human breast cancer (TOP) and lung adenocarcinoma (BOTTOM).
SW-48 cell lysate was resolved by electrophoresis, transferred to nitrocellulose and probed with purified anti-human DcR3, clone B08-35.
The DcR3 protein is a soluble member of the TNF receptor superfamily containing four TNF receptor domains with an approximate molecular weight of 35 kD. DcR3, also known as Decoy receptor 3, TR6, M68, can be secreted by monocytes and myeloid-derived dendritic cells following exposure to bacterial antigens. DcR3 is overexpressed in tumors including lung and colon cancers, gliomas, and pancreatic cancers and can be detected in the serum of cancer patients. DcR3 can also be found in the cytoplasm and endoplasmic reticulum in some cell types. This protein competes for ligand binding with cell surface receptor and can inhibit their signaling. DcR3 has been shown to bind the ligands FasL, LIGHT, and TNF like molecule 1 (TL1A) to inhibit binding to the cell surface receptors Fas, HVEM and LT-ßR, and death receptor 3 (DR3), respectively.
Other Names:
Decoy receptor 3, TR6, M68
Structure:
Soluble member of the TNF superfamily (6B), contains four TNF-receptor like domains, approximate molecular weight 35 kD.
Distribution:
Secreted protein, also found in cytoplasm and endoplasmic reticulum. Expressed by monocytes and myeloid-derived dendritic cells following exposure to bacterial antigens. Overexpressed in tumors including lung and colon cancers, gliomas and pancreatic canc
Function:
Competes with ligand binding to surface receptors including FasL binding to Fas, LIGHT binding to HVEM and LT-ßR, and TNF like molecule 1 (TL1A) with death receptor 3 (DR3). Competition inhibits cell-surface receptor signaling.
Interaction:
Binds FasL, LIGHT, and TL1A
Antigen References:
1. Pitti RM, et al. 1998. Nature 396:699. 2. Bai C, et al. 2000. Proc. Natl. Acad. Sci. USA 97:1230. 3. Yu KY, et al. 1999. J. Biol. Chem. 274:13733. 4. Migone TS, et al. 2002. Immunity 16:479.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/terms). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.
This data display is provided for general comparisons between formats. Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors. If you need assistance with selecting the best format contact our expert technical support team.
Purified anti-human DcR3
Formalin-fixed, paraffin-embedded human tissues were stained with 5 µg/ml B08-35, followed by incubation with biotinylated goat anti-mouse secondary antibody, followed by HRP-streptavidin. Staining was visualized with DAB peroxidase substrate and counterstained with hematoxylin. Immunohistochemical staining of DcR3 expression is shown for human breast cancer (TOP) and lung adenocarcinoma (BOTTOM).
SW-48 cell lysate was resolved by electrophoresis, transferred to nitrocellulose and probed with purified anti-human DcR3, clone B08-35.